Patients with cancers of the gullet, stomach and bowel respond well to new anti-HER2 drug
(ECCO-the European CanCer Organisation) An antibody that binds simultaneously to two distinct regions of the HER2 receptor to block the growth of cancer cells has shown promising signs of anti-tumor activity in a number of cancers including those of the gullet (esophagus), stomach and bowel.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
More News: Cancer | Cancer & Oncology | Esophagus Cancer | Gastric (Stomach) Cancer | HER2 | Oesophagus